The Journal · Volume 02
Explore the research
Briefs that help you understand what researchers study — how strong the evidence is, what remains open, and how the compounds show up in the literature. 63 essays. Tap a card to open the full brief.
Your Muscle Noticed Menopause. Science Still Points at Iron.
After menopause, honestly/Nov 5, 2026
Your Muscle Noticed Menopause. Science Still Points at Iron.
Midlife muscle loss is real, quiet, and not in your head. Here's what the training research actually backs, and why the internet's favorite growth-hormone peptide stack still hasn't earned a muscle claim.
Read brief → 3 min · Human clinical trial · Regulatory context
Your Tendons Are Still Running on Your Teenage Collagen
Recovery, honestly
Your Tendons Are Still Running on Your Teenage Collagen
Your muscles rebuild all the time. The core of your Achilles mostly doesn't. Here's what actually toughens tendons, what collagen peptide trials found, and where the "Wolverine" peptides really stand.
Read brief → 3 min/Human clinical trial, Early human research, Early lab / animal research
The Holiday Pound Is Small. It Just Never Leaves.
Weight, honestly
The Holiday Pound Is Small. It Just Never Leaves.
The famous five-pound holiday gain is a myth. The real number is smaller, and that's the problem. Here's what a holiday trial says works, and what your gut's own fullness peptides have to do with it.
Read brief → 3 min/Human clinical trial, Early human research, Regulatory context
Semax Just Got a Hall Pass. Your Brain Still Wants a Walk.
Longevity, honestly
Semax Just Got a Hall Pass. Your Brain Still Wants a Walk.
Washington just cleared the way for pharmacies to make the "brain peptide" Semax. That's a permission slip, not a report card. Here's what actually has data for a sharper brain as you age.
Read brief → 3 min/Human clinical trial, Early lab / animal research, Regulatory context
Your Best Growth Hormone Spike Happens in Bed
Recovery, after dark
Your Best Growth Hormone Spike Happens in Bed
Your body's biggest growth hormone pulse shows up in deep sleep. The surprise: in trials, more growth hormone made muscles bigger on the scale, not stronger in the gym.
Read brief → 4 min/Human clinical trial, Regulatory context
Your GLP-1 Has an Off Switch. Your Workout Doesn't.
Weight, after the shot
Your GLP-1 Has an Off Switch. Your Workout Doesn't.
The weight-loss peptides work while they're on board. When people stop, most of the weight drifts back. One habit had better staying power than the drug did.
Read brief → 3 min/Human clinical trial, Approved drug (different product context)
Hot Flashes Have a Peptide Problem, Not a Peptide Fix
After menopause
Hot Flashes Have a Peptide Problem, Not a Peptide Fix
Hot flashes really do run partly on a brain peptide. The approved fixes don't add a peptide. They're pills that turn that signal down, and the non-prescription habits with the best evidence aren't the ones you'd guess.
Read brief → 4 min/Approved drug (different product context), Human clinical trial, Early human research
"Ozempic Face" Is Real. It's Also Mostly Math.
Skin, honestly
"Ozempic Face" Is Real. It's Also Mostly Math.
Faces change when weight changes, and GLP-1 drugs change weight fast. The first real measurements say "Ozempic face" is mostly the face doing its share of the math, not a special drug effect, at least so far.
Read brief → 3 min/Early human research, Human clinical trial, Approved drug (different product context)
From One Knob to Four: Why Rat Wins Rarely Become Human Ones
Weight-loss check
From One Knob to Four: Why Rat Wins Rarely Become Human Ones
Four-in-one weight-loss peptides are beating approved drugs in rat studies. Here's how we got from one hormone to four, where the human trials actually stand, and why a rat win is a rehearsal, not opening night.
Read brief → 4 min/Early lab / animal research, Human clinical trial, Regulatory context
Your NAD+ Went Up. Your Body Didn't Notice.
Longevity, honestly
Your NAD+ Went Up. Your Body Didn't Notice.
NAD+ pills and drips are everywhere. The new trials show they really do raise the number. What they haven't shown yet is that the number changes how you age.
Read brief → 3 min/Human clinical trial, Early human research, Early lab / animal research
BPC-157 Is Finally Getting a Real Hamstring Test
Recovery, honestly
BPC-157 Is Finally Getting a Real Hamstring Test
A pulled hamstring is the gym injury that keeps coming back. The boring fixes have real trials behind them, and the internet's favorite recovery peptide just got its first real human test.
Read brief → 3 min/Human clinical trial, Early lab / animal research, Early human research, Regulatory context
Food Noise Has a Second Volume Knob. It's Called Amylin.
Weight, honestly
Food Noise Has a Second Volume Knob. It's Called Amylin.
That constant snack chatter in your head has a name now. The habits that quiet it have receipts, and the hormone behind Novo's next weight-loss shot is still waiting on the FDA.
Read brief → 3 min/Human clinical trial, Approved drug (different product context), Regulatory context
The Best-Proven Peptides After Menopause Are Bone Drugs
Bone check
The Best-Proven Peptides After Menopause Are Bone Drugs
The peptide forums talk about glow and longevity. The peptides with the biggest trials behind them for women after menopause are prescription bone drugs, and the best habit is a barbell.
Read brief → 3 min/Approved drug (different product context), Human clinical trial
Trevogrumab Isn't a Muscle Peptide. It's an Antibody in a Trial.
Weight-loss check
Trevogrumab Isn't a Muscle Peptide. It's an Antibody in a Trial.
Forums call it a "muscle peptide" for people on GLP-1s. It's actually a big lab-grown antibody that has only been tested in a company trial, and it isn't approved anywhere.
Read brief → 4 min/Human clinical trial, Regulatory context
Your Sunscreen Has Better Skin Data Than Your Collagen
Skin check
Your Sunscreen Has Better Skin Data Than Your Collagen
Collagen powder is the internet's favorite skin peptide. The independent trials keep coming up empty, while a four-year sunscreen trial quietly did the job.
Read brief → 4 min/Human clinical trial, Early human research
Cartalax Has Only Met Cartilage in a Dish
Longevity check
Cartalax Has Only Met Cartilage in a Dish
Longevity forums call Cartalax a joint "bioregulator" for aging well. It's three amino acids, Epitalon minus one, and it has only been tested on cells and rats.
Read brief → 4 min/Early lab / animal research, Human clinical trial
IGF-1 LR3 Was Built for Lab Dishes, Not Biceps
Recovery, honestly
IGF-1 LR3 Was Built for Lab Dishes, Not Biceps
Gym forums call IGF-1 LR3 the growth factor that rebuilds you overnight. Its real job is feeding cells in a factory tank, and it has never been tested in people.
Read brief → 3 min/Early lab / animal research, Human clinical trial, Approved drug (different product context)
The Fat-Burning Peptide That Couldn't Beat a Dummy Pill
Weight, honestly
The Fat-Burning Peptide That Couldn't Beat a Dummy Pill
AOD-9604 is sold as the fat-burning slice of growth hormone. Its biggest human trial says the real star was the meal plan.
Read brief → 3 min/Human clinical trial, Early lab / animal research, Regulatory context
MOTS-c Is Not a Workout in a Vial
Strong after menopause
MOTS-c Is Not a Workout in a Vial
After menopause, the scale can hold still while muscle and bone quietly slip. Lifting has real women behind it. The buzzy "exercise peptide" so far has mice.
Read brief → 4 min/Human clinical trial, Early human research, Early lab / animal research, Regulatory context
Argireline Is Not Botox in a Bottle
Skin check
Argireline Is Not Botox in a Bottle
The serum peptide was built to copy Botox's trick. Two small trials disagree, and your moisturizer might be doing more of the work than the label admits.
Read brief → 4 min/Human clinical trial, Early human research, Early lab / animal research, Regulatory context
ARA-290 Isn't an Anti-Aging Peptide. It's an Unfinished Drug.
Longevity check
ARA-290 Isn't an Anti-Aging Peptide. It's an Unfinished Drug.
The healthspan buzz comes from old rats. The human trials measured nerves in the eye, and then the company ran out of road.
Read brief → 3 min/Human clinical trial, Early lab / animal research, Regulatory context
The Wolverine Stack Didn't Beat One Peptide in Rats
Recovery check
The Wolverine Stack Didn't Beat One Peptide in Rats
Gym forums swear two recovery peptides are better together. The first head-to-head rat study of that stack just said otherwise. Your sleep still does more work than either vial.
Read brief → 5 min/Early lab / animal research, Regulatory context
The 12% Belly-Fat Shot Measured One Slice of the Loaf
Headline check
The 12% Belly-Fat Shot Measured One Slice of the Loaf
A shot that cut “dangerous organ fat by 12%” is all over your feed. The number is real. It also comes from about 40 people, one slice of an MRI, and a meeting abstract nobody has peer-reviewed yet.
Read brief → 5 min/Human clinical trial, Early lab / animal research, Regulatory context
Glutathione Is Not a Glow Drip
Naming trap
Glutathione Is Not a Glow Drip
This summer, “glow” drips of glutathione sent people to the hospital. The ingredient wasn’t exotic. It was made for capsules, not veins. Here’s why “pure” and “injectable” are different words.
Read brief → 5 min/Regulatory context, Human clinical trial
A Stopgap Is Not an Approval
Regulatory context
A Stopgap Is Not an Approval
This week’s headlines say Washington may let pharmacies sell BPC-157 and five other peptides for now. Nothing has actually changed yet, and even if it does, “allowed for now” is not “proven.”
Read brief → 4 min/Regulatory context, Early lab / animal research, Early human research
Melanotan I Is Not Scenesse
Naming trap
Melanotan I Is Not Scenesse
The tanning peptide on your feed has a twin with an FDA approval. Same 13 building blocks. One is a doctor-placed implant for a rare sun-pain disease. The other is a powder in a vial.
Read brief → 5 min/Early human research, Human clinical trial, Approved drug (different product context), Regulatory context
CBL-514 Is Not a Peptide
Naming trap
CBL-514 Is Not a Peptide
The “fat-cell eraser” shot your feed keeps asking about is a small-molecule drug that just started Phase 3. It isn’t a peptide, it isn’t approved, and no research vial can stand in for it.
Read brief → 5 min/Early lab / animal research, Human clinical trial, Regulatory context, Approved drug (different product context)
Kisspeptin Is Not a Testosterone Booster
Naming trap
Kisspeptin Is Not a Testosterone Booster
It’s named after a chocolate, it started life as a cancer gene, and your feed calls it a natural testosterone booster. The real story is better: kisspeptin is a doorbell, and holding the bell down can make the house go quiet.
Read brief → 5 min/Early human research, Human clinical trial, Regulatory context
Higher-Dose Tirzepatide Is Not a Bigger Vial
Dose race
Higher-Dose Tirzepatide Is Not a Bigger Vial
Wegovy got a higher dose this spring, and Lilly is testing tirzepatide above its label. That trial hasn’t shared a number yet. And the big number on a research vial was never a dose.
Read brief → 5 min/Human clinical trial, Regulatory context, Approved drug (different product context)
Survodutide Is Not a Research GLP Vial
Two knobs
Survodutide Is Not a Research GLP Vial
Survodutide turns GLP-1 and glucagon on one weekly shot. Fresh Phase 3 numbers in people with obesity and type 2 diabetes are not a research-vial remix — and not yesterday’s four-knob peptide that skipped glucagon.
Read brief → 5 min/Human clinical trial, Regulatory context
Four Knobs, and None of Them Is Glucagon
Four knobs
Four Knobs, and None of Them Is Glucagon
PTT-A is one peptide aimed at GLP-1, GIP, amylin, and calcitonin. Glucagon is not the fourth knob. The muscle story is a company rat abstract — and a TikTok photo of the slide is not a human result.
Read brief → 5 min/Early lab / animal research, Regulatory context
An Oral Peptide Is Not Putting the Vial in a Capsule
Oral identity
An Oral Peptide Is Not Putting the Vial in a Capsule
Search “oral peptide” and you get three different objects: approved peptide tablets with an absorption trick, a GLP-1 pill that is not a peptide, and research vials plus gray-market capsules. Pouring vial powder into a gelcap is none of them.
Read brief → 5 min/Approved drug (different product context), Human clinical trial, Early lab / animal research, Regulatory context
Is the Next Weight-Loss Capsule Already Named?
Next capsule
Is the Next Weight-Loss Capsule Already Named?
The future of weight loss is loud, and NA-931 is one name in that conversation: a real sponsor code, not a public four-way capsule recipe.
Read brief → 5 min/Early human research, Early lab / animal research, Regulatory context
Is the Future of Weight Loss Already Here?
Landscape
Is the Future of Weight Loss Already Here?
TikTok keeps calling four-knob peptides “already here.” The honest ladder is simpler: labeled incretins you can name today, late-stage amylin and triple stacks still in trials, and tetra/quintuple molecules that so far live mostly in rat abstracts — with the real plot twist being fat loss versus muscle loss.
Read brief → 5 min/Approved drug (different product context), Human clinical trial, Early lab / animal research, Regulatory context
Peptides for Women Is Not a Protocol
Naming trap
Peptides for Women Is Not a Protocol
Feeds sell “peptides for women” and “premenopause stacks” like one pink protocol. Midlife body-composition change is a real research story. A single vial menu is not. Different molecules, different evidence grades, different labeled-product fences — and a lot of hallway talk.
Read brief → 5 min/Human clinical trial, Approved drug (different product context)
DSIP Is Not a Sleep Protocol
Naming trap
DSIP Is Not a Sleep Protocol
Forums treat DSIP like a delta-wave remote control because the name says “Delta Sleep-Inducing Peptide.” The rabbit isolation story is real. The later human insomnia trials were small, mixed, and often underwhelming — and a 2006 review still called the sleep-factor claim a poorly documented riddle.
Read brief → 5 min/Early human research, Early lab / animal research
Oxytocin Is Not a Bonding Protocol
Naming trap
Oxytocin Is Not a Bonding Protocol
Feeds call oxytocin the “love hormone” and treat a research vial like a bonding protocol. Oxytocin is a real nine-amino-acid neuropeptide — and a hospital drug with a narrow obstetric label (Pitocin). The emoji nickname and the product identity are not the same file.
Read brief → 5 min/Human clinical trial, Approved drug (different product context), Regulatory context
KPV Is Not a Compounding Green Light
Regulatory hype
KPV Is Not a Compounding Green Light
Peptide feeds treat a July 2026 FDA advisory vote like the agency cleared compounding for KPV. The mouse inflammation papers are real. A green light on the 503A Bulks List is not.
Read brief → 5 min/Early lab / animal research, Regulatory context
Epitalon Is Not a Telomere Longevity Protocol
Longevity hype
Epitalon Is Not a Telomere Longevity Protocol
Longevity feeds still sell Epitalon (Epithalon / AEDG) like dish telomere length already equals human longevity. Cell papers are real. A modern Western RCT for systemic AEDG as anti-aging medicine is not.
Read brief → 5 min/Early lab / animal research, Early human research
FOXO4-DRI Is Not a Longevity Protocol
Longevity hype
FOXO4-DRI Is Not a Longevity Protocol
Longevity TikTok still screenshots FOXO4-DRI (sometimes written Proxofim) like human aging evidence already exists. One famous 2017 Cell mouse paper is real. Published human trials of that peptide are not.
Read brief → 5 min/Early lab / animal research, Regulatory context
SLU-PP-332 Is Not a Research Peptide
Naming trap
SLU-PP-332 Is Not a Research Peptide
TikTok shelves “SLU-PP-332” next to research peptides and calls it an exercise mimetic. The mouse papers are real. The peptide label is not — it’s a small-molecule tool compound from a Saint Louis University chemotype, not a chain of amino acids.
Read brief → 5 min/Early lab / animal research, Regulatory context
Melanotan II Is Not PT-141
Naming trap
Melanotan II Is Not PT-141
TikTok treats “the tanning peptide” and “PT-141” like nicknames for the same vial. They sit on the same melanocortin family tree. Only one of them has an FDA-approved drug story — and it isn’t a sunless-tan product.
Read brief → 5 min/Early human research, Human clinical trial, Approved drug (different product context), Regulatory context
Orforglipron is not a research GLP vial: An oral small-molecule pill (Foundayo), not a peptide, and not ILGLP-*
Regulatory
Orforglipron is not a research GLP vial: An oral small-molecule pill (Foundayo), not a peptide, and not ILGLP-*
Orforglipron (LY3502970) is a once-daily oral non-peptide GLP-1 receptor agonist. Foundayo is Lilly’s labeled tablet for weight management — not a lyophilized peptide research vial, and not ILGLP-1, ILGLP-2, or ILGLP-3.
Read brief → 10 min/Early lab / animal research, Human clinical trial, Regulatory context, Approved drug (different product context)
Thymosin α1: A different thymic peptide — and a large sepsis trial that did not move mortality
Compound
Thymosin α1: A different thymic peptide — and a large sepsis trial that did not move mortality
A 28-residue thymic peptide with a real international drug story under the name thymalfasin — and a 2025 multicenter sepsis trial that found no clear mortality benefit. Not Thymosin β4. Not TB-500.
Read brief → 9 min/Human clinical trial, Regulatory context, Early lab / animal research
What a peptide actually is
Methods
What a peptide actually is
A short chain of amino acids — the same building blocks as proteins, stopped before a full fold. Here is why that length still matters in cells, and how a research vial fits the picture.
Read brief → 7 min/Lab method, Early lab / animal research
How GLP-1 changed metabolic research
Compound
How GLP-1 changed metabolic research
An incretin hormone with a deep physiology literature — and, later, large human trials on labeled products. Inspired Labs ILGLP-1 is a research analog in that conversation, not a prescription pen.
Read brief → 9 min/Human clinical trial, Approved drug (different product context)
CJC-1295 + Ipamorelin: Two different paths to the growth-hormone axis
Compound
CJC-1295 + Ipamorelin: Two different paths to the growth-hormone axis
One is a long-acting GHRH analog that kept IGF-1 elevated for days in healthy adults. The other is a selective ghrelin-receptor secretagogue with a distinctive hormone panel in animals. A blend is two literatures sharing a vial.
Read brief → 9 min/Human clinical trial, Early lab / animal research
TB-500 and Thymosin β4: Why the difference matters
Compound
TB-500 and Thymosin β4: Why the difference matters
Thymosin β4 is a 43-residue actin-binding protein with a real rodent wound literature. Catalog “TB-500” is usually a shorter actin-binding motif. Length changes what experiment you are actually reading.
Read brief → 8 min/Early lab / animal research, Regulatory context
PT-141 and the melanocortin system: A different kind of peptide story
Compound
PT-141 and the melanocortin system: A different kind of peptide story
Bremelanotide won FDA approval in 2019 for acquired, generalized HSDD in premenopausal women. Two Phase 3 trials in 1,247 women moved desire and distress scores. A research vial of PT-141 sits in the same receptor conversation — as a chemical, not as that autoinjector.
Read brief → 8 min/Approved drug (different product context), Human clinical trial
Semax and Selank: Two peptides with an unusual history in Russian neuroscience
Compound
Semax and Selank: Two peptides with an unusual history in Russian neuroscience
One raises hippocampal BDNF in rats and has a Russian stroke literature. The other was compared with a benzodiazepine in 62 patients with generalized anxiety. Neither carries an FDA indication as a focus drug.
Read brief → 9 min/Early lab / animal research, Early human research
NAD+: The molecule connecting cellular energy, metabolism, and aging research
Compound
NAD+: The molecule connecting cellular energy, metabolism, and aging research
Levels of this coenzyme fall with age in many tissues. Precursors reverse pieces of that story in mice. Human evidence is real, uneven, and mostly about NMN and NR — adjacent to, and not identical with, a lyophilized dinucleotide on a research shelf.
Read brief → 8 min/Early lab / animal research, Early human research
GLOW and KLOW: Why blends need separate evidence stories
Compound
GLOW and KLOW: Why blends need separate evidence stories
BPC-157, TB-500, and GHK-Cu did not meet in a landmark blend trial. They met in a catalog. KLOW adds KPV. Each sequence has its own papers, gaps, and evidence grade.
Read brief → 8 min/Early lab / animal research, Early human research
How to read a certificate of analysis
Methods
How to read a certificate of analysis
A COA is a lot-specific lab record. Match the lot, check the method, and separate identity from purity — that is most of the skill.
Read brief → 8 min/Lab method
What Research Use Only actually means
Regulatory
What Research Use Only actually means
RUO is an intended-use boundary in plain English: the product is for laboratory research, not for diagnosing, treating, or curing disease — and a footer disclaimer cannot rewrite a product story that points the other way.
Read brief → 9 min/Regulatory context
GHK-Cu: The copper peptide with decades of research behind it
Compound
GHK-Cu: The copper peptide with decades of research behind it
Loren Pickart isolated GHK from human plasma in the 1970s. The copper complex that followed built a real dermal literature — worth reading on its own terms.
Read brief → 10 min/Early lab / animal research, Early human research
BPC-157: Why the animal research gets so much attention
Compound
BPC-157: Why the animal research gets so much attention
The pentadecapeptide has a large preclinical literature — especially in rodents — and a much thinner human file. FDA has been explicit about that gap.
Read brief → 9 min/Early lab / animal research, Regulatory context
SS-31: From mitochondrial research peptide to an FDA-approved drug
Compound
SS-31: From mitochondrial research peptide to an FDA-approved drug
Elamipretide received accelerated approval as Forzinity for Barth syndrome in September 2025. The research material and the approved product share a story — and they are not interchangeable.
Read brief → 8 min/Approved drug (different product context), Early lab / animal research
Reconstitution is just dilution math
Methods
Reconstitution is just dilution math
Mass, diluent volume, and syringe units are a measurement problem — useful for preparing a known concentration in the lab, and distinct from any dosing instruction.
Read brief → 7 min/Lab method
MOTS-c: The tiny peptide encoded inside mitochondrial DNA
Compound
MOTS-c: The tiny peptide encoded inside mitochondrial DNA
A 16-residue peptide from the mitochondrial genome, with AMPK-linked metabolic work in mice — and no approved human drug.
Read brief → 8 min/Early lab / animal research, Regulatory context
Tesamorelin and Egrifta: Related sequences, different products
Compound
Tesamorelin and Egrifta: Related sequences, different products
A GHRH analogue with an FDA-approved product for HIV-associated lipodystrophy. Sequence relatedness is real; product identity is a separate question.
Read brief → 8 min/Approved drug (different product context), Human clinical trial
5-Amino-1MQ: Why researchers are targeting the NNMT enzyme
Compound
5-Amino-1MQ: Why researchers are targeting the NNMT enzyme
Nicotinamide N-methyltransferase sits in a metabolic literature around NAD+ and methylation. A small-molecule inhibitor is a tool for asking those questions carefully.
Read brief → 8 min/Early lab / animal research
Why endotoxin testing belongs on a peptide COA
Methods
Why endotoxin testing belongs on a peptide COA
LAL is a quantitative method with units and a detection story. “Looks clean” is not a specification — and cell assays notice the difference.
Read brief → 7 min/Lab method
How this journal grades evidence
Methods
How this journal grades evidence
Six plain labels — from lab method to approved-drug context — so a mouse study, a cream trial, and a labeled product do not blur into one caption.
Read brief → 6 min/Lab method
The catalog
Interested in compounds you've been reading about?
Explore the Inspired Labs research catalog for lot-level documentation and pricing on the compounds discussed in these briefs.